Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: MYL
- CUSIP: 62853010
- Previous Close: $42.33
- 50 Day Moving Average: $38.68
- 200 Day Moving Average: $39.36
- 52-Week Range: $33.60 - $50.40
- Trailing P/E Ratio: 84.83
- Foreward P/E Ratio: 7.94
- P/E Growth: 1.00
- Market Cap: $22.65B
- Outstanding Shares: 535,105,000
- Beta: 1.14
- Net Margins: 2.50%
- Return on Equity: 22.04%
- Return on Assets: 8.43%
Companies Related to Mylan:
- Debt-to-Equity Ratio: 1.10%
- Current Ratio: 0.83%
- Quick Ratio: 0.55%
What is Mylan's stock symbol?
Mylan trades on the NASDAQ under the ticker symbol "MYL."
Where is Mylan's stock going? Where will Mylan's stock price be in 2017?
19 brokers have issued twelve-month price targets for Mylan's stock. Their forecasts range from $44.00 to $70.00. On average, they anticipate Mylan's share price to reach $52.00 in the next twelve months.
When will Mylan announce their earnings?
Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns Mylan stock?
Mylan's stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (3.73%), FIL Ltd (0.81%), Appaloosa LP (0.61%), Menora Mivtachim Holdings LTD. (0.55%), Dimensional Fund Advisors LP (0.43%) and Renaissance Technologies LLC (0.28%). Company insiders that own Mylan stock include Heather M Bresch, John D Sheehan, Joseph C Md Maroon, Mark W Parrish, Melina E Higgins, Robert J Cindrich, Robert J Coury and Wendy Cameron.
Who sold Mylan stock? Who is selling Mylan stock?
Mylan's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, FMR LLC, Allianz Asset Management AG, AQR Capital Management LLC, Putnam Investments LLC, RidgeWorth Capital Management LLC, TCW Group Inc. and Mayo Investment Advisers LLC. Company insiders that have sold Mylan stock in the last year include Heather M Bresch and Robert J Coury.
Who bought Mylan stock? Who is buying Mylan stock?
Mylan's stock was acquired by a variety of institutional investors in the last quarter, including Appaloosa LP, Renaissance Technologies LLC, State Street Corp, Russell Investments Group Ltd., Raymond James Financial Services Advisors Inc., Yost Capital Management L.L.C., Hodges Capital Management Inc. and Baird Financial Group Inc.. Company insiders that have bought Mylan stock in the last two years include Joseph C Md Maroon, Mark W Parrish, Melina E Higgins, Robert J Cindrich and Wendy Cameron.
How do I buy Mylan stock?
Shares of Mylan can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Mylan stock cost?
One share of Mylan stock can currently be purchased for approximately $42.33.